Antimicrobial Prophylaxis in Urology with special reference to the new Quinolones

1. Front Matter

   Pages I-VIII

   PDF

2. Introduction

   1. Introduction

      • Thomas C. Gasser

      Pages 1-2

3. General Considerations

   1. General Considerations

      • Thomas C. Gasser

      Pages 3-11

4. In Vitro Studies

   1. In Vitro Studies

      • Thomas C. Gasser

      Pages 12-12

5. Animal Studies

   1. Animal Studies

      • Thomas C. Gasser

      Pages 13-17

6. Human Studies and Review of the Literature

   1. Human Studies and Review of the Literature

      • Thomas C. Gasser

      Pages 18-30

7. Literature

   1. Literature

      • Thomas C. Gasser

      Pages 31-38

8. Summary

   1. Summary

      • Thomas C. Gasser

      Pages 39-39

9. Acknowledgments

   1. Acknowledgments

      • Thomas C. Gasser

      Pages 40-40

10. Reprints of papers I – VII

    1. Front Matter

       Pages 41-41

       PDF

    2. The Influence of Various Body Fluids and pH on E. Coli MIC of Quinolone Derivatives

       • T. C. Gasser, E. H. Larsen, T. Dørflinger, P. O. Madsen

       Pages 43-46

    3. Quinolone Penetration into Canine Vaginal and Urethral Secretions

       • T. C. Gasser, P. H. Graversen, E. H. Larsen, T. Dørflinger

       Pages 47-51

    4. Fleroxacin (Ro 23-6240) Distribution in Canine Prostatic Tissue and Fluids

       • Thomas C. Gasser, Peder H. Graversen, Paul O. Madsen

       Pages 53-56

    5. Vergleichende Pharmakokinetik in der Prostata

       • T. C. Gasser, P. H. Graversen, E. H. Larsen, P. O. Madsen

       Pages 57-62

    6. Ciprofloxacin Pharmacokinetics in Patients with Normal and Impaired Renal Function

       • Thomas C. Gasser, Steven C. Ebert, Peder H. Graversen, Paul O. Madsen

       Pages 63-66

    7. Treatment of Complicated Urinary Tract Infections with Ciprofloxacin

       • Thomas C. Gasser, Peder H. Graversen, Paul O. Madsen

       Pages 67-68

    8. Antimicrobial Prophylaxis in Urology: Timing, Dosing, and Duration Studies with special reference to High-risk conditions

       • Thomas C. Gasser, Paul O. Madsen

       Pages 69-76

This monograph gives an excellent review of the issue of antimicrobial prophylaxis in urol­ ogy and the use of the new fluoroquinolones in urology. The development of the fluoro­ quinolones has had a profound effect in urology, specifically because of the unique phar­ macokinetics of the fluoroquinolones with their two or more pK values, making concen­ tration of these compounds possible in the prostate. Their wide spectra against infecting organisms causing infections in the urinary tract have also made them popular and almost ideal in the treatment of urinary tract infections. This thesis summarizes in an concise way and brings up to date practically all our know­ ledge concerning the use of fluoroquinolones in urology. The chapter on antimicrobial prophylaxis covers our present knowledge completely, especially concerning the use of these drugs in antimicrobial prophylaxis in transurethral surgery. September 1992 PaulO. Madsen Madison, Wisconsin, USA v Contents Preface. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . V I. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1. 1. Author's Publications Referred to in Text . . . . . . . . . . . . . . . . . . . . . . 1 1. 2. Historical Background . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1. 3. Problems of Antimicrobial Prophylaxis in Urology . . . . . . . . . . . . . . . . 2 D. General Considerations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 2. 1. Definitions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 2. 1. 1. Bacteriuria and urinary tract infections . . . . . . . . . . . . . . . . . . . . . . 3 2. 1. 2. Bacteremia and septicemia .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 2. 1. 3. Nosocomial infections . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 2. 1. 4. Wound infections . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 2. 2. Pathophysiology of Infection . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 2. 3. Specifics of Antimicrobial Agents to be Used in Prophylaxis . . . . . . . . . . 6 2. 4. Role of Quinolones . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6 2. 4. 1. Antimicrobial activity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6 2. 4. 2. Pharmacokinetic properties . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

• Transplantation
• antimicrobial
• antimicrobial prophylaxis
• bacteremia
• bacteria
• infection
• infections
• infectious
• infectious disease
• nosocomial infection
• pathophysiology
• physiology
• infectious diseases

• Urologic Clinics Department of Surgery, University Hospital (Kantonsspital), Basel, Switzerland

  Thomas C. Gasser

Policies and ethics